Hemogenyx Pharmaceuticals PLC Announces Clearance to Proceed with Pediatric Expansion
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Regulatory Clearance to Proceed with Pediatric Expansion of HG-CT-1 Clinical Trial
LONDON, UK / / June 17, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that the 30-day review period by the U.S. Food and Drug Administration (FDA) for the Company's previously submitted amendment to the clinical protocol of its ongoing Phase I trial of HG-CT-1 has concluded without a clinical hold. As a result, the Company is now cleared to proceed with the next steps required to initiate pediatric enrolment in the trial.
The protocol amendment expands the eligibility criteria for the Phase I trial of HG-CT-1, Hemogenyx's proprietary CAR-T therapy for relapsed/refractory acute myeloid leukemia (R/R AML), to include children and adolescents with this aggressive and hard-to-treat disease.
The Company will now move forward with Institutional Review Board (IRB) submissions and associated site activation procedures to enable the opening of pediatric cohorts.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:"Regulatory clearance to proceed with the pediatric expansion of our HG-CT-1 clinical trial is a significant milestone. It reflects continued momentum in our development program and underscores our commitment to delivering innovative therapies to patients across age groups. This expansion broadens the potential impact and value of HG-CT-1 as we continue to advance toward key inflection points in the clinic. Importantly, it also reinforces the value of Company's robust intellectual property portfolio, which underpins our pipeline and supports long-term strategic growth."
The Company will update the market as further progress is made in pediatric site activation and patient enrolment.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
Hemogenyx Pharmaceuticals plc
https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder
headquarters@hemogenyx.com
Peter Redmond, Director
peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP
Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited
Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
15 minutes ago
- USA Today
Gummy vitamins sold at Amazon and Aldi recalled. See impacted products.
Gummy vitamins sold at Amazon and Aldi recalled. See impacted products. Show Caption Hide Caption 6 signs you might have a vitamin B12 deficiency Vitamin B12 is essential for producing energy and some research has shown that it can help with depression and prevent dementia. unbranded - Lifestyle Certain vitamin gummies sold on Amazon and at Aldi and BJ's Wholesale Club locations nationwide were recalled for potentially containing an undeclared allergen. Vita Warehouse Corp. voluntarily issued the recall on Thursday, June 12, for one lot of B12 vitamin gummies under brand names Welby, Berkley Jensen and VitaGlobe, according to a news release issued by the Food and Drug Administration (FDA). The undeclared allergen that triggered the recall was peanuts, the release said. Individuals with an allergy or severe sensitivity to peanuts "run the potential risk of serious or life-threatening allergic reactions if they consume these products," according to the federal agency. Here is what to know about the ongoing recall: Which vitamins were recalled? The recalled vitamins include: Aldi Welby (1,000 microgram, 140 gummies): Clear bottle with white cap, using green, red, and white labeling. UPC Code : 4099100290868 Lot # : 248046601* Expiration Date : 10/2026* (1,000 microgram, 140 gummies): Clear bottle with white cap, using green, red, and white labeling. Berkley Jensen (1,000 microgram, 250 gummies): Clear bottle with white cap, using red and pink labeling. UPC Code : 888670132487 Lot # : 248046601* Expiration Date : 10/2026* (1,000 microgram, 250 gummies): Clear bottle with white cap, using red and pink labeling. VitaGlobe (extra strength, 60 gummies): Clear bottle with white cap, using white and red labeling. UPC Code : 850005214670 Lot # : 248046601* Expiration Date : 10/2026* (extra strength, 60 gummies): Clear bottle with white cap, using white and red labeling. *Lot code and expiration date are printed on the bottom of the bottle. Has anyone gotten sick from consuming the affected vitamins? The recalled vitamins have not led to any reported illnesses or allergic reactions, according to the FDA. How was the undeclared allergen found? The recall was issued after Aldi conducted a routine testing as part of the retailer's standard protocol to verify the accuracy of allergen-related claims made on products' labeling, specifically a 'does not contain peanuts' statement, the FDA said. One of the test results showed a potential presence of a peanut allergen, the agency added. Although Vita Warehouse Corp.'s internal testing verified the absence of peanuts in the vitamins, the "recall is being initiated out of an abundance of caution to ensure consumer safety and trust," according to the FDA. No other Welby, Berkley Jensen and VitaGlobe brand products are affected by this recall. What should people with peanut allergies do if they bought the recalled vitamins? Those who are allergic to peanuts and have purchased the affected vitamins with the lot code 248046601 and an expiration date of October 2026 are "urged to return them to the place of purchase for a full refund or discard them immediately," according to the FDA. Any consumer who experiences an allergic reaction should seek medical attention right away, the agency said. Vita Warehouse Corp. can be contacted at 1-855-214-0100 Monday-Friday from 7:30 am – 4 p.m. EST to answer questions.
Yahoo
21 minutes ago
- Yahoo
Spanish bank BBVA tells wealthy clients to invest in bitcoin
By Iain Withers LONDON (Reuters) -Spanish lender BBVA is advising wealthy clients to invest up to 7% of their portfolio into cryptocurrencies, an executive said on Tuesday, in the latest sign some banks are warming to a sector long avoided by mainstream finance because of its risks. BBVA's private bank advises clients to invest 3% to 7% of their portfolio in cryptocurrencies depending on their risk appetite, Philippe Meyer, head of digital & blockchain solutions at BBVA Switzerland, told the DigiAssets conference in London. "With private customers, since September last year, we started advising on bitcoin," Meyer said. "The riskier profile, we allow up to 7% of (portfolios in) crypto." Cryptocurrency prices have surged in recent years, with bitcoin hitting another record high in May. That follows a recovery from lows hit in 2022 when a series of top exchanges, including FTX, collapsed, leaving millions of investors out of pocket. Their rebound has been helped by U.S. President Donald Trump's pro-crypto stance. While many private banks execute client requests to buy cryptocurrencies, it is relatively unusual for them to advise them to actively buy them. Regulators continue to warn about the risks of cryptocurrencies, saying investors should expect to lose all their money. The European Securities and Markets Authority said earlier this year that 95% of EU banks do not engage in crypto activities. Speaking to Reuters on the sidelines of the event, Meyer told Reuters he believed BBVA was one of the first large global banks to advise its wealthy clients to buy cryptocurrencies. It had been executing on client requests to buy them since 2021, he said. The 3-7% advice currently applies to bitcoin and ether, but BBVA plans to expand the advice to other cryptocurrencies later this year, he said. Meyer said that clients had been receptive so far to the advice, and dismissed concerns the asset was too risky. "If you look at a balanced portfolio, if you introduce 3% you already boost the performance," Meyer said. "At 3% you are not taking a huge risk." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
21 minutes ago
- Forbes
Will The EU Roll Back 2035 EV Monopoly Target To Save Its Industry?
The European Union's plan for a new electric vehicle monopoly by 2035 will falter as sales disappoint and China's EV push gains momentum. Brussels faces an uncomfortable choice: water down its green transition, or risk the health of its flagship auto industry. The EU is being urged to dilute its plan that new EVs will be the only game in town by 2035 by widening the possibilities with hybrids and e-fuels. Green groups are adamant EVs should be the only option. Industry experts say EU regulations to curb CO2 emissions in the name of saving the planet are having unfortunate side effects. They are exposing Europe's carmakers to an existential threat from China not only in home markets but in global markets too. Leading mass carmakers like Stellantis and Volkswagen are being forced to close factories. Their global markets are being undermined as well. Even the likes of Germany's BMW, Mercedes and Audi are being exposed in the electrification stakes. The EU has raised tariffs on electric cars from China by an extra 17% to 35.3%, on top of the existing 10% car import duty. But this hasn't slowed China's business much because of its huge lead in efficiency. Chinese manufacturers have also switched their focus to plug-in hybrids which don't carry the extra tariff. The EU is between a rock and a hard place. Save the auto industry and millions of jobs by watering down the CO2 regulations and be accused of climate change denial. Or maintain the hard line, please environmental lobby groups, and weaken the industry. Politics will decide on this issue, which has become a left/right controversy. The left has traditionally been on the side of climate change absolutists. The right has been more willing to compromise. Recent elections for the EU, and the member states, have shown a move to the right, but it's not yet clear if this will herald a change of policy. In mid-2021 when the EU drew up its plan to phase out the sale of new combustion engine vehicles by 2035 in favour of EVs, it didn't look like a death sentence for its auto industry. But now some believe it does. China is geared up to flood the global market with EVs, hybrids and plug-in hybrids. Not to mention conventional ICE products. It is said to have at least a 30% efficiency advantage. 'China speed' has become a cliché in the industry, referring to its ability to design and build state-of-the-art sedans and SUVs about twice as quickly as traditional automakers. 'What we have right now in Europe is regulation that might have been designed to benefit the Chinese carmakers. They are prepared. They are ahead of the Europeans,' said Felipe Munoz, global automotive analyst at JATO Dynamics. 'It needs to change,' Munoz said in an email exchange. 'Politicians are not seeing what's going on in the factories and the market-place. They are not aligned with reality,' he said. Munoz said it's not only the Chinese impact in Europe that is dangerous, it's the impact in regions where European automakers have been very strong and profitable. Here the Chinese are making big progress. The EU has decreed that automakers raise their EV market share in 2025 to 28% and ratchet up to about 80% by 2030 and 100% by 2035. The trouble is auto buyers aren't cooperating. Sales forecasts by consultants and investment banks for 2030 point to about half of the 80%. Investment bank UBS recently slashed almost two million EVs from its sales forecast for Europe in 2030. That now stands at 6.4 million or 37.8%. Other forecasts include BMI, a part of Fitch Solutions, 35%, French automotive consultancy Inovev 40%, and investment researcher Jefferies 35%. And according to a survey published by oil giant Shell, drivers in Europe are becoming more reluctant to switch to electric vehicles from combustion engines. The survey of 15,000 drivers across the world showed that 41% of respondents in Europe would consider switching to an electric car compared with 48% last year. The main negatives were the cost of vehicles, and high prices for public charging. Shell operates 75,000 charging stations in Europe, the U.S. and China. The European Automobile Manufacturers Association said in a statement that it has voiced concerns about how the transition to climate neutrality has not progressed as expected, as the market uptake of battery-electric models has been slower than anticipated. 'However, to stay on course we urgently need a holistic approach to ensure that the industry remains competitive and resilient whilst investing in emission reduction technologies. This includes: Brussels-based Transport & Environment is adamant that no concessions should be made to those seeking to dilute the rules, not only on environmental grounds, but says any mitigation will also make it more difficult for European carmakers to repel the Chinese threat. 'Weakening the 2030 CO2 target or reversing the 2035 decision is also a misguided global industrial policy. It would allow European carmakers to take their foot off the gas and delay investment in mass-market EV models they need to compete globally,' T&E's Julia Poliscanova said. 'The world's politics are certainly bumpy, but electrification is accelerating regardless. If Europe wants battery investment, affordable EV models and a competitive auto industry globally, it starts with standing firm on the 2035 zero-emissions mandate,' Poliscanova said. Poliscanova was rebutting a plea by the German automaker's association, VDA, that wants to weaken the 2035 ICE deadline by exempting plug-in hybrids and low-carbon gasoline. The EU has already weakened the rules for 2025 by allowing manufacturers to average out their CO2 emissions over an extra two years. Last week Stellantis chairman John Elkann called on the EU to change its rules to allow automakers to return to building entry-level small cars, along the lines of Japan's so called 'Kei' cars. As part of the 2035 CO2 emissions agreement manufacturers were given concessions which allowed them to make extremely heavy and profitable SUVs and sedans. But the EU also included regulations virtually outlawing the sale of little gasoline-powered vehicles like the Fiat 500 which became impossibly expensive. JATO's Munoz also wants the regulations widened. 'We need to change the whole approach and consider other ways. By all means keep the goals but allow other solutions as well. So far it's been limited to electric vehicles but anything that lowers CO2 emissions should be welcome. The brand that has made the most progress in Europe in cutting CO2 emissions is Toyota with its hybrids, but it doesn't sell many electric vehicles. You can reduce emissions not only by selling EVs but hybrids too,' Munoz said. The EU Commission will later this year review the whole mandate for 2035, including the possibility of "full technology neutrality" as a core principle. That would mean withdrawing from the notion that politicians could pick winning technologies and generate automaker euphoria and green anger.
